Detalles de la búsqueda
1.
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Anticancer Drugs
; 35(6): 559-562, 2024 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38453158
2.
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Cancer Immunol Immunother
; 72(11): 3707-3716, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37638980
3.
Comparing a Part with the Whole: Beware of the Disparity of the Renal Cell Carcinoma Prognostic Models.
Ann Surg Oncol
; 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833057
4.
Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
Int J Urol
; 2024 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38825971
5.
Treatment of metastatic TFE3 microphthalmia transcription factor translocation renal cell carcinoma: a case report.
Transl Pediatr
; 13(3): 499-507, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38590368
6.
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Clin Genitourin Cancer
; 22(2): 126-133.e2, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37932204
7.
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Clin Exp Metastasis
; 2024 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38850317
8.
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
Clin Genitourin Cancer
; 22(3): 102074, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38616147
9.
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Target Oncol
; 2024 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704759
10.
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.
Eur Urol
; 2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38521617
11.
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.
Technol Cancer Res Treat
; 22: 15330338231159753, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36855829
12.
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Expert Rev Anticancer Ther
; 23(5): 545-554, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017710
13.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Front Biosci (Elite Ed)
; 15(3): 20, 2023 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743233
14.
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
J Natl Cancer Inst
; 115(12): 1605-1615, 2023 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37563779
15.
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?
Urol Oncol
; 40(5): 202, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35430140
Resultados
1 -
15
de 15
1
Próxima >
>>